Talent Intelligence impactful to an Enterprise

This week we worked on various aspects of making Talent Intelligence impactful to an Enterprise. At Draup, we firmly believe all the complex analyses we conduct should drive more reskilling and more talented and qualified individuals to your enterprise.   Sometimes, we forget this grounding view.  Yes, the great presentations and dashboards are great, but we will always strive for stories where we make an impact/assisting in making the impact.  We have a great case study this week to share, and hopefully, you will find this useful

As we all know, 2021 has started with a significant emphasis on hiring across locations and industries.  The war for talent has become real.  In markets where the technology product players and VCs operate, we find the Hiring Difficulty getting higher for all Digital Talent. (Software, Core Engineering functions like Electrical Engineering and Data Engineering and many other similar categories)  Corporate functions talent is also at a premium with heavy premium associated with Finance, HR, Digital Marketing, Legal and Compliance, Sustainability roles.  This is not very surprising given what is happening

• Global VC funds invested is well over 300 Billion in 2020 (Despite COVID-19, this is record growth)
• Private Equity Companies raised well over 530 Billion in 2020
• Enterprises increased their R&D funds by well over 1.5 Trillion dollars (Approximate Estimate- estimates in this category often vary a bit depending upon what is called R&D)

All this means the war for talent is only going to get tough.  While our analysis can bring in all the data you need, we want to emphasize in this email the Agile process and Lean Management principles that will be useful for Recruitment.  Along with this, Enterprises also need to realize that Recruiting is also a bit abstract, and qualitative aspects matter more.  There is a famous case study documented by Safi Bahcall – An American Physicist. Amgen and Biogen both tried to hire University of Chicago Professor Eugene Goldwasser.  Goldwasser was key in taking one of their drugs to the next level as he held the key to a winning protein. The purified protein developed by Goldwasser contained the code to making the drug.  Both the companies fought hard for Goldwasser and his protein. Goldwasser decided to join Amgen and decided to give Amgen the protein vial rather than its main competitor, Biogen. The only differentiating reason between Amgen and Biogen?- Biogen’s CEO had refused to pick up the check for dinner one night.  The drug that was subsequently developed erythropoietin, or EPO for short, turned out to be far, far more successful than anyone imagined.

Last month we experimented with a large telecom and 5G provider.  Our experiments resulted in closing 500 positions in less than 17 days for a mix of software and network-related roles.  This was a great collective achievement by the team.  Any output like this, the team gets more credit than the data supplier.  As a result, what I am writing is only a collective story, and our part is a small part of that

Let us look at the steps taken in this experiment.  At the outset, we decided to do certain things differently